Kincell Bio has completed a $22 million funding round led by NewSpring Capital and Kineticos Life Sciences to accelerate its cGMP capabilities and process development services for cell therapies.
Senti Biosciences presented positive preliminary data from its Phase 1 trial of SENTI-202, showing 5 of 7 evaluable patients with relapsed/refractory AML achieved objective responses, including 4 complete remissions that were all MRD-negative.
Senti Bio's SENTI-202, a gene circuit-enabled CAR-NK cell therapy, achieved MRD-negative complete remission in 2 of 3 relapsed/refractory AML patients at the lowest dose level in its Phase 1 trial, with both patients maintaining remission.
Full Circles Therapeutics has received USPTO patent allowance for its C4DNA™ GATALYST™ platform, enabling precise genome modification using circular single-stranded DNA without viral vectors.